Objectives-Small dense HDL3 particles of defined lipidome and proteome potently protect atherogenic LDL against free radical-induced oxidation; the molecular determinants of such antioxidative activity in these atheroprotective, antiinflammatory particles remain indeterminate. Methods and Results-Formation of redox-active phosphatidylcholine hydroperoxides (PCOOH) and redox-inactive phosphatidylcholine hydroxides (PCOH) was initiated in LDL by free radical-induced oxidation. Human HDL3 inactivated LDL-derived PCOOH (Ϫ62%, PϽ0.01) and enhanced accumulation of PCOH (2.1-fold, PϽ0.05); in parallel, HDL3 accumulated minor amounts of PCOOH. Enzyme-deficient reconstituted dense HDL potently inactivated PCOOH (Ϫ43%, PϽ0.01). HDL3-mediated reduction of PCOOH to PCOH occurred concomitantly with oxidation of methionine residues in HDL3-apolipoprotein AI (apoAI). Preoxidation of methionine residues by chloramine T markedly attenuated PCOOH inactivation (Ϫ35%); by contrast, inhibition of HDL3-associated enzymes was without effect. PCOOH transfer rates from oxidized LDL to phospholipid liposomes progressively decreased with increment in the rigidity of the phospholipid monolayer. Conclusions-The redox status of apoAI and surface lipid rigidity represent major determinants of the potent HDL3-mediated protection of LDL against free radical-induced oxidation. Initial transfer of PCOOH to HDL3 is modulated by the surface rigidity of HDL3 particles with subsequent reduction of PCOOH to PCOH by methionine residues of apoAI. Key Words: small dense HDL Ⅲ surface rigidity Ⅲ methionine residues Ⅲ reduction Ⅲ apolipoprotein AI Ⅲ lipid hydroperoxides O xidative stress, an emerging risk factor for premature atherosclerosis and cardiovascular disease, mediates formation of proinflammatory proatherogenic oxidized low-density lipoprotein (oxLDL) in the arterial intima. 1 Both 1-electron (lipophilic and hydrophilic free radicals) and 2-electron (hypochlorite, peroxynitrite) oxidants contribute to LDL oxidation in vivo. 1 Accordingly, oxLDL contains multiple products of free radical-induced lipid peroxidation, including lipid hydroperoxides (LOOH) as primary products, secondary LOOH-derived short-chain oxidized phospholipids (oxPL), and oxidized sterols. 1 Significantly, oxLDL can induce a proinflammatory phenotype in arterial wall cells, which contributes to both endothelial dysfunction and the atherogenic process. 2 High-density lipoprotein (HDL) protects LDL from oxidative damage by free radicals and therefore exerts antiinflammatory properties. Indeed, HDL particles inhibit accumulation of primary and secondary peroxidation products in LDL. 2 Such antioxidative and antiinflammatory effects of HDL are manifested in animal models as attenuated production of reactive oxygen species and diminished expression of endothelial adhesion proteins, and are associated with attenuated atherogenesis. 2, 3 HDL particles are, however, highly heterogeneous in their structure, metabolism, and biological functions. 4 Among the major HDL subpopulations, small, dense, protein-rich HDL3 are distinguished by their proteome and lipidome. 5, 6 Furthermore, HDL3 exhibit potent capacity to protect LDL from free radical-induced oxidative damage 7 and to inhibit oxLDLinduced apoptosis of endothelial cells. 8 Atheroprotective properties of small dense HDL3 are consistent with results of clinical and animal studies. 9,10 Such antioxidative activity
O xidative stress, an emerging risk factor for premature atherosclerosis and cardiovascular disease, mediates formation of proinflammatory proatherogenic oxidized low-density lipoprotein (oxLDL) in the arterial intima. 1 Both 1-electron (lipophilic and hydrophilic free radicals) and 2-electron (hypochlorite, peroxynitrite) oxidants contribute to LDL oxidation in vivo. 1 Accordingly, oxLDL contains multiple products of free radical-induced lipid peroxidation, including lipid hydroperoxides (LOOH) as primary products, secondary LOOH-derived short-chain oxidized phospholipids (oxPL), and oxidized sterols. 1 Significantly, oxLDL can induce a proinflammatory phenotype in arterial wall cells, which contributes to both endothelial dysfunction and the atherogenic process. 2 High-density lipoprotein (HDL) protects LDL from oxidative damage by free radicals and therefore exerts antiinflammatory properties. Indeed, HDL particles inhibit accumulation of primary and secondary peroxidation products in LDL. 2 Such antioxidative and antiinflammatory effects of HDL are manifested in animal models as attenuated production of reactive oxygen species and diminished expression of endothelial adhesion proteins, and are associated with attenuated atherogenesis. 2, 3 HDL particles are, however, highly heterogeneous in their structure, metabolism, and biological functions. 4 Among the major HDL subpopulations, small, dense, protein-rich HDL3 are distinguished by their proteome and lipidome. 5, 6 Furthermore, HDL3 exhibit potent capacity to protect LDL from free radical-induced oxidative damage 7 and to inhibit oxLDLinduced apoptosis of endothelial cells. 8 Atheroprotective properties of small dense HDL3 are consistent with results of clinical and animal studies. 9, 10 Such antioxidative activity appears to derive from both nonenzymatic and enzymatic components of HDL3 7 ; however, its precise molecular features remain indeterminate.
Apolipoprotein AI (apoAI), the major HDL apolipoprotein, may play a central role in HDL-mediated antioxidation, as Met residues 112 and 148 can reduce LOOH into redox-inactive lipid hydroxides (LOH), thereby terminating chain reactions of lipid peroxidation. 11, 12 In addition, apoAI attenuates LDL oxidation by removal of seeding LOOH molecules from LDL. 13 Enzymatic components potentially contributing to antioxidative activity of HDL include paraoxonase 1 (PON1), plateletactivating factor-acetyl hydrolase (PAF-AH or "lipoproteinassociated phospholipase A2") and lecithin:cholesterol acyltransferase (LCAT), 4 all of which were proposed to hydrolyze proinflammatory short-chain oxPL (see 14 for review). 14 However, PON1, PAF-AH, and LCAT are weakly reactive toward LOOH. [15] [16] [17] [18] Recent proteomic studies have demonstrated that small dense HDL3 particles are enriched in apoAI, apoF, apoJ, apoL-I, PLTP, PON1, PAF-AH, and LCAT. 5, 6 Furthermore, the HDL3 lipidome is deficient in sphingomyelin, 6 a structural lipid with positive impact on surface rigidity and negative impact on LCAT activity, thereby implicating surface phospholipids (PL) in the biological activities of HDL. Indeed, the transfer of LOOH from LDL to HDL can occur, either spontaneously or mediated by lipid transfer proteins, directly between lipoprotein PL monolayers. 19, 20 Our present goal was to dissect the molecular features of the HDL3-mediated protection of LDL from free radicalinduced oxidative damage. We reveal that the potent antioxidative activity of HDL3 critically involves the transfer of phospholipid hydroperoxides (PLOOH) from oxLDL to HDL3 in a process dependent on HDL surface lipid rigidity, with subsequent inactivation of LDL-derived PLOOH by Met residues of apoAI.
Methods
Our experimental strategy involved (1) isolation of HDL2 (a mixture of HDL2a and 2b subclasses) and HDL3 (a mixture of HDL3b and 3c subclasses) particles by density gradient ultracentrifugation, (2) cooxidation of HDL and LDL by 2,2Ј-azobis-(2-amidinopropane) hydrochloride (AAPH), an azo-initiator of lipid peroxidation, 21 and (3) coincubation of HDL with LDL preoxidized by AAPH. Details of this strategy, and of: (1) reagents and chemicals, (2) blood samples, (3) fractionation and characterization of plasma lipoproteins, (4) preparation of reconstituted HDL (rHDL) and liposomes, (5) determination of phosphatidylcholine hydroperoxides (PCOOH), phosphatidylcholine hydroxides (PCOH), cholesteryl ester hydroperoxides (CEOOH), PL, cholesteryl esters (CE), lysophosphatidylcholine (lysoPC), free fatty acids, and oxidized Met residues of apoAI by HPLC, (6) the capacity of HDL to protect LDL from oxidative damage, (7) the rigidity of liposomal PL monolayers, and (8) the activities of HDL-associated enzymes, are available in the supplemental materials (available online at http://atvb.ahajournals.org). Data presented are meansϮSD of at least 3 independent experiments with at least 3 independent HDL samples. Table I ) during LDL oxidation by AAPH. Indeed, levels of PCOOH tended to be lower (Ϫ58%) in LDLϩHDL3 mixtures as compared to LDL oxidized alone after 2-hour incubation and were significantly decreased at 6 hours (Ϫ48%, PϽ0.05; supplemental Figure IA) . Furthermore, PCOOH levels in LDLϩHDL3 mixtures were reduced as compared to those in LDL and HDL3 oxidized separately (supplemental Table II ). In parallel, reduction in PCOOH levels was observed in LDL reisolated from LDLϩHDL3 mixtures after oxidation for 2 hours (Ϫ65%) and 6 hours (Ϫ44%, PϽ0.05; supplemental Figure IB ). During oxidation, small amounts of PCOOH accumulated in reisolated HDL3 (supplemental Figure IC) .
Results

Inactivation of PCOOH and CEOOH During LDL؉HDL3 Oxidation
PCOOH
Large light HDL2 tended to attenuate levels of PCOOH in LDLϩHDL2 mixtures after 2-hour and 6-hour oxidation (Ϫ50% and Ϫ44% as compared to LDL oxidized alone respectively; nϭ4, Pϭns). In LDL reisolated from LDLϩHDL2 mixtures, PCOOH concentrations tended to fall (Ϫ62% and Ϫ26% at 2 hours and 6 hours, respectively; nϭ4, Pϭns). Accumulation of PCOOH was significantly more pronounced in reisolated HDL2 as compared to that in reisolated HDL3 (6.6-fold at 2 hours and 2.8-fold, PϽ0.05, at 6 hours; nϭ4), consistent with greater rates of oxidation in LDLϩHDL2 versus LDLϩHDL3 mixtures.
CEOOH
CEOOH levels in LDL (the sum of the 18:2 and 20:4 molecular species; supplemental Table I ) were diminished in the presence of HDL3. Indeed, CEOOH levels tended to diminish in LDLϩHDL3 mixtures as compared to LDL oxidized alone after both 2-hour and 6-hour oxidation (Ϫ38% and Ϫ26% respectively; supplemental Figure IIA) . A marked reduction in CEOOH content in the presence of HDL3 (Ϫ50%) was noted in LDL reisolated from mixtures with HDL3 after 2 hours (supplemental Figure IIB) . Overall, the effect of HDL3 on CEOOH accumulation in LDL was less potent than that on PCOOH. In parallel, accumulation of CEOOH was detected in reisolated HDL3 (supplemental Figure IIC) .
Similarly, CEOOH concentrations tended to decrease in the presence of HDL2 both in LDLϩHDL2 mixtures (Ϫ35% and Ϫ29% after 2 hours and 6 hours, respectively; nϭ4, Pϭns) and in reisolated LDL (Ϫ48% after 2 hours; nϭ4, Pϭns). CEOOH accumulation was markedly higher in reisolated HDL2 as compared to reisolated HDL3 (4.0-fold and 4.7-fold difference; nϭ4) after oxidation for 2 hours and 6 hours (PϽ0.05), respectively.
Inactivation of PLOOH and CEOOH in Preoxidized LDL
PCOOH
In separate experiments, LDL were preoxidized and subsequently incubated with HDL in the presence of EDTA. After 2-hour incubation, PCOOH levels in LDLϩHDL3 mixtures were significantly decreased (Ϫ42%, PϽ0.01; Figure 1A ) as compared to oxLDL alone. Even greater effects on PCOOH levels were noted after prolonged (6-hour) incubation (Ϫ62%, PϽ0.01; Figure 1A ). Consistent with these data, HDL3 potently inactivated PCOOH in oxLDL reisolated after 0.5-hour incubation (Ϫ64%, PϽ0.01; Figure 1B ), an effect which was even more pronounced at 2 hours (Ϫ87%, PϽ0.001) and at 6 hours (Ϫ95%, PϽ0.001; Figure 1B ). In reisolated HDL3, slow accumulation of PCOOH was observed ( Figure 1C ) consistent with the transfer of PLOOH from oxLDL.
HDL2 equally attenuated PLOOH content in preoxidized LDL, albeit less markedly than HDL3 when compared on a total mass basis. Indeed, PCOOH levels were significantly decreased by HDL2 both in LDLϩHDL2 mixtures (Ϫ25% and Ϫ53%, PϽ0.05, after 2-hour and 6-hour oxidation, respectively; Figure 1A ) and in reisolated oxLDL (Ϫ72%, PϽ0.01, Ϫ80%, PϽ0.001, and Ϫ90%, PϽ0.001, after 0.5-hour, 2-hour, and 6-hour oxidation respectively; Figure 1B ). In reisolated HDL, PCOOH levels were preferentially elevated (15-fold) in HDL2 as compared to HDL3 after 0.5-hour incubation, and were 5-fold and 4-fold elevated after 2 hours and 6 hours, respectively ( Figure 1C ).
CEOOH
In striking contrast, no change in CEOOH concentrations was observed in oxLDLϩHDL3 mixtures incubated under the same conditions (supplemental Figure IIIA) . Likewise, no effect of HDL3 on CEOOH content in oxLDL reisolated after coincubation was observed (supplemental Figure IIIB) . Reisolated HDL3 slowly accumulated low CEOOH levels (supplemental Figure IIIC) , thereby resembling the pattern of PCOOH accumulation ( Figure 1C) . Similarly, no effect of HDL2 on CEOOH content of preoxidized LDL was observed (data not shown). However, CEOOH accumulation was considerably more pronounced in reisolated HDL2 than in reisolated HDL3 (approximately 30-fold after 0.5-hour and 2-hour oxidation and 23-fold after 6 hours; nϭ4, PϽ0.05).
HDL-Mediated Inactivation of PCOOH: Role of ApoAI
To define the role of apoAI in the HDL-mediated inactivation of PCOOH, rHDL containing only purified apoAI and palmitoyloleoyl phosphatidylcholine (POPC) at a molar ratio of 1.0/77.1 were prepared. Importantly, the size and density of such rHDL closely resemble those of small dense HDL3. 22 When such enzyme-deficient, small, dense rHDL were incubated with oxLDL for 2 hours at 37°C, PCOOH levels were significantly decreased (Ϫ43%) as compared to those in oxLDL incubated alone (2.37Ϯ0.40 versus 3.96Ϯ0.95 mol/L respectively, nϭ3; PϽ0.01). Furthermore, such rHDL displayed potent activity in the LDL oxidation assay; indeed, significant reduction (Ϫ64%, PϽ0.05; Table) in the propagation rate of lipid peroxidation in LDL incubated with apoAI/POPC complexes as compared to LDL oxidized alone was observed. ApoAI/POPC rHDL equally induced a pronounced prolongation of the propagation phase (ϩ104%) and a moderate decrease in the maximal diene concentration (Ϫ27% ; Table) . The capacity of such rHDL to protect LDL from oxidative damage was comparable to that of small dense HDL3b ϩ3c isolated from control human plasma 5 (Ϫ79% decrement in the propagation rate, ϩ57% increment of the propagation phase duration and Ϫ27% decrement in the LDL (10 mg TC/dL) were incubated with AAPH (1 mmol/L) in the absence or presence of rHDL (10 mg total protein/dl) in PBS at 37°C: rHDL prepared by cholate dialysis contained either apoA-I/POPC (molar ratio, 1.0/77.1), apoA-I/ POPC/FC (molar ratio, 1.0/66.4/5.1), or apoA-I/(POPC/SPM); molar ratio, 1.0/65.8. In some experiments rHDL was preincubated with chloramine T (see Figure 2 for details). Oxidation of LDLϩrHDL mixtures was compared to LDL oxidized alone and measured as the increment in absorbance at 234 nm. Data are meansϮSD of 3 independent experiments with 2 independent LDL samples. *PϽ0.05 vs LDL alone.
maximal diene concentration when recalculated to equivalent concentration of protein of 10 mg/dL; nϭ11).
Implication of Met Residues of ApoAI in HDL-Mediated Inactivation of PCOOH
Met sulfoxide-containing forms of apoAI represented 9.5Ϯ2.3% (nϭ9) of total apoAI in freshly isolated HDL3, suggesting that some Met oxidation occurs in the circulation in vivo or during HDL isolation in vitro. 12 After incubation of HDL3 in the presence of oxLDL, both redox-active Met residues of apoAI (Met112 and 148) were significantly transformed (by 58% and 79% after 0.5 hours and 2 hours, respectively) into the corresponding sulfoxides (Figure 2A) , thereby demonstrating that inactivation of LDL-derived PCOOH by HDL3 was associated with the conversion of apoAI Met into Met(O). Furthermore, concomitant formation of PCOH occurred, which was accelerated by the presence of HDL3. Indeed, levels of PCOH were elevated 2.1-fold in the presence of HDL3 (PϽ0.05) and were accompanied by significant reduction in PCOOH levels (Ϫ59%; Figure 2B ; PϽ0.05), resulting in the 5.6-fold elevated PCOH/PCOOH ratio (0.67 versus 0.12).
To further evaluate the role of Met residues in the capacity of HDL to inactivate PCOOH, chloramine T was used to selectively oxidize apoAI Met112 and Met148. 11 Both apoAI Met residues were fully oxidized by chloramine T (data not shown); such HDL3 revealed diminished capacity to inactivate PCOOH, resulting in increased PCOOH levels (ϩ33%; supplemental Figure IVA) . In parallel, a minor increase (ϩ10%) in PCOOH was observed in oxLDL reisolated from the mixture of oxLDL and HDL3 pretreated with chloramine T as compared to oxLDL reisolated from the mixture with native HDL3 (supplemental Figure IVB) . Marked increment in PCOOH occurred in reisolated HDL3 pretreated with chloramine T as compared to native HDL3 (ϩ350%, PϽ0.05; supplemental Figure IVC) . As a result, levels of PCOH in oxLDLϩHDL3 mixtures were significantly decreased (Ϫ70%; supplemental Figure IVD) in the presence of HDL3 pretreated with chloramine T as compared to native HDL3, resulting in a 4.2-fold diminished PCOH/PCOOH ratio.
Finally, apoAI Met residues were selectively oxidized with chloramine T in rHDL. The antioxidative activity of such chloramine T-pretreated rHDL was markedly decreased, both in terms of its capacity to decrease LDL oxidation rate and to prolong LDL oxidation (Table) . Furthermore, treatment of apoAI/POPC rHDL with chloramine T diminished (Ϫ45%) its capacity to inactivate oxLDL-derived PCOOH as compared to nontreated rHDL (PCOOH levels at the end of the incubation, 3.08Ϯ0.70 mol/L versus 2.37Ϯ0.40 respectively; nϭ3).
Implication of HDL-Associated Enzymes in HDL3-Mediated Inactivation of PCOOH
To evaluate the potential role of HDL-associated enzymes, including LCAT, PAF-AH, and PON1, in the inactivation of LDL-derived LOOH, HDL3 was pretreated with a cocktail of enzymatic inhibitors (DFP which inhibits all 3 enzymes, Pefabloc which selectively inhibits PAF-AH, and EDTA which selectively inhibits PON1; supplemental Table III) and then incubated with oxLDL. Pretreatment significantly decreased the activities of HDL-associated LCAT (Ϫ50%), PAF-AH (Ϫ90%), and PON1 (Ϫ99%; supplemental Figure  VA) . However, no decrease in the capacity of such HDL3 to inactivate LOOH in oxLDL (supplemental Figure VB) or to delay LDL oxidation (data not shown) was observed. Similarly, no significant loss of the capacity of HDL3 to delay the accumulation of conjugated dienes in LDL was noted as a result of the pretreatment of HDL3 with any given single inhibitor (supplemental Table III ).
In a separate experiment, HDL3 was preincubated with DTNB to derivatize free SH-groups involved in LCAT and PON1 activities. 11, 23 Again, such treatment exerted no influence on HDL3 capacity to inactivate preformed LOOH (data not shown). As expected, treatment of HDL3 with DTNB did not cause oxidation of Met residues of apoAI (data not shown). Finally, 10-minute incubation of HDL3 at 56°C significantly decreased PON1 and LCAT activities but did not influence its capacity to delay LDL oxidation (supplemental Table III) .
To evaluate the role of hydrolytic enzymes, products of hydrolytic degradation of PC were equally determined. Levels of lysoPC in reisolated LDL oxidized alone and in oxLDL reisolated from oxLDLϩHDL3 mixtures after 6-hour oxidation were similar (2.11Ϯ1.02 versus 1.75Ϯ1.25 mol/L, respectively; nϭ3). Furthermore, no difference was observed between lysoPC levels in HDL3 reisolated from LDLϩHDL3 mixtures after 6-hour oxidation and nonoxidized HDL3 (1.00Ϯ0.44 versus 0.97Ϯ0.31 mol/L respectively; nϭ3). Finally, after 6-hour incubation, no accelerated accumulation of free fatty acids was noted in LDLϩHDL3 mixtures versus LDL alone (40.0Ϯ4.1 versus 43.5Ϯ4.9 mol/L respectively; nϭ3).
Implication of Surface PL in the HDL-Mediated Inactivation of PCOOH: Role of Acceptor Monolayer Rigidity
To elucidate whether PCOOH could be transferred to acceptor particles from oxLDL, oxLDL was incubated with LOOH-free PC liposomes prepared from nonoxidable POPC. Indeed, PCOOH accumulation in the liposomes was observed with concomitant decrease in PCOOH content of oxLDL (Ϫ50%, PϽ0.001; Figure 3A ). To investigate whether such PCOOH transfer depended on physical characteristics of the acceptor PL monolayer, liposomal membrane rigidity was varied by adding sphingomyelin (SM) or free cholesterol (FC). On addition of 30 mol% SM to POPC, transfer of PCOOH to acceptor liposomes was diminished by Ϫ10%; addition of 10 and 30 mol% FC decreased PCOOH transfer from oxLDL by Ϫ20% and Ϫ25%, respectively ( Figure 3A) . As a result, the rigidity of the liposomal PL monolayer, assessed as generalized polarization (GP) of Laurdan fluorescence, was strongly and negatively correlated with PCOOH transfer (rϭϪ0.98, Pϭ0.02; Figure 3B ).
LDL was then oxidized in the presence of small dense rHDL containing either apoAI/POPC, apoAI/POPC/FC, or apoAI/ (POPCϩSM). The propagation rate of LDL oxidation was significantly higher in the presence of apoAI/POPC/FC and apoAI/POPC/SM rHDL (ϩ53%, PϽ0.05, and ϩ46%, PϽ0.01, respectively; Table) as compared to LDL oxidized in the presence of apoAI/POPC rHDL. In parallel, the propagation phase was markedly shortened in the presence of apoAI/POPC/FC and apoAI/POPC/SM rHDL Ϫ113%, PϽ0.07, and Ϫ106%, PϽ0.06, respectively; Table) . By contrast, no difference in the maximal diene concentration was observed between different rHDL preparations, consistent with data for plasma HDL known to influence the rate, rather than the total amount, of LOOH accumulation under the oxidative conditions employed. 7 
Kinetic Analysis of LDL and HDL Oxidation
Kinetic analysis of LDL and HDL oxidation performed according to Bowry and Stocker 21 revealed that the lipid peroxidation rate (R p ) in LDL was decreased by 55% as a result of the addition of HDL3 (supplemental Table IV ). The lipid peroxidation rate of HDL3 was markedly (up to 21-fold) lower as compared to those for LDL. Importantly, the sum of R p values obtained for LDL and HDL3 oxidized the same mixture was lower as compared to the value of R p obtained for LDL oxidized alone, indicative of the protective effect of HDL toward LDL oxidation.
Discussion
Our present investigations have identified 2 key determinants of the potent capacity of physicochemically-defined HDL3 particles to protect LDL from oxidative damage by free radicals. Firstly, the HDL PL monolayer, which ensures the transfer of PLOOH from LDL to HDL3 in a process modulated by HDL surface lipid rigidity, and secondly apoAI, which reduces PLOOH to the corresponding redox-inactive PLOH by virtue of Met residues. By contrast, our data does not support the contention that HDL-associated enzymes (ie, PON1, PAF-AH, and LCAT) contribute significantly to the inactivation of LDL-derived LOOH.
We have established that the rigidity of the PL monolayer of HDL particles is a key modulator of the transfer efficiency of PCOOH from LDL to HDL. Indeed, the strong negative correlation of the PLOOH transfer rate to liposomes with membrane rigidity emphasizes the importance of both physical and chemical properties in this process. Furthermore, both the PLOOH transfer rate from oxLDL and the capacity of HDL to delay LDL oxidation decreased in parallel with surface lipid rigidity in rHDL.
The spontaneous translocation of PL-derived LOOH between erythrocytes and LDL is established. 24 LOOH transfer equally occurs between plasma lipoproteins in systems consisting of donor/acceptor vesicles and rHDL. 19, 20 Lipid transfer proteins, including cholesteryl ester transfer protein (CETP), can accelerate the transfer of both PLOOH and CEOOH between plasma lipoproteins. 19, 20 As HDL and LDL are the major vehicles for transport of PL and CE in plasma, exchange of LOOH with other lipoproteins (eg, VLDL) should be of secondary importance. Clearly then, the transfer of LDL-associated PLOOH to HDL constitutes a key step in the HDL-mediated attenuation of LDL lipid peroxidation.
Consistent with the earlier data of Stocker et al, 11 ,12 HDL3-associated apoAI inactivated LDL-derived PLOOH with reduction to the corresponding PLOH; apoAI methionine residues 112 and 148 presumably constitute the site of such reduction. 11, 12 Indeed, concentrations of redox-active Met residues in apoAI and of PLOOH in our assay ranged from 1.9 to 4.5 mol/L and from 1.2 to 4.7 mol/L, respectively, consistent with a 1:1 reaction stoichiometry. Kinetic analysis revealed that lipid peroxidation rate of HDL3 was markedly lower as compared to that of LDL despite similar molar content of oxidizable fatty acids in HDL3 and LDL. 6, 25 Furthermore, the sum of lipid peroxidation rates in LDL and in HDL3 oxidized in the mixture was considerably lower than that of LDL oxidized alone under identical conditions. As simple inhibition of oxidation by the addition of less oxidizable substrate can be excluded, these data provide direct evidence for HDL3 as a site of the inactivation of LDL-derived LOOH on exposure to oxidative stress.
Oxidation of specific Met residues in apoAI and apoAII to Met(O) plays a major role in the two-electron reduction of PCOOH and CEOOH in HDL particles. 11, 12 In addition, lipid-free apoAI can prevent formation of LDL-derived oxidized PL by the removal of LOOH from LDL or arterial wall cells 13 ; LOOH reduction by apoAI Met residues may contribute significantly to such an antioxidative effect. Importantly, rHDL containing only purified apoAI and POPC, but devoid of enzymatic components, and authentic small, dense HDL3b ϩ3c, were comparable in their capacities to delay lipid peroxidation of LDL. ApoAI therefore constitutes the central element in the HDL3-mediated protection of LDL from free radical-induced oxidation. This conclusion is consistent with the potent capacity of HDL3 to inactivate LOOH as HDL3 is enriched in apoAI as compared to HDL2. 6 The dissociation of PON1 activity from the capacity of HDL to inactivate LOOH indicates that HDL-associated PON1 does not contribute significantly to the inactivation of LDL-derived LOOH. We and others 11, 26 demonstrated the existence of PON1-independent antioxidative activity of HDL. The major activity of PON1 has been recently demonstrated as that of a lactonase rather than a peroxidase 17 ; the affinity of PON1 for LOOH is several orders of magnitude lower than its affinity for lactones. 17, 27 Together with our present data, these findings demonstrate that LOOH do not constitute a significant substrate of PON1 and that the previously proposed mechanism for the PON1-mediated attenuation of LDL lipid peroxidation via hydrolysis of LOOH is not tenable. We hypothesize therefore that the established antiatherosclerotic properties of PON1 28 are unrelated to its capacity to inactivate LOOH, but rather involve its major activity as a lactonase through a still unknown pathway upstream of the regulation of systemic oxidative stress.
In a similar manner, plasma PAF-AH readily hydrolyzes PAF-like oxPL 29 ; furthermore, PAF-AH can hydrolyze PLOOH, 18 leading to the formation of lysoPC and a fatty acid hydroperoxide. In our studies, inhibition of PAF-AH by Pefabloc was without effect on the HDL-mediated inactivation of LDL-derived LOOH, thereby indicating that PAF-AH cannot account for this activity. LCAT may equally hydrolyze short-chain oxidized PC generated during lipoprotein oxidation, 15 but is inactive toward oxidized CE, the most abundant oxidized lipid species in LDL. 1 Data herein demonstrate that LCAT is at most a minor factor in LOOH inactivation.
We propose a 2-step mechanism for the HDL3-mediated protection of LDL against oxidative damage by 1-electron oxidants (Figure 4 ). Initially PLOOH is transferred from LDL to HDL3; such transfer is governed by the rigidity of the surface monolayer of HDL, decelerates with increasing rigidity, and can be facilitated by lipid transfer proteins, such as CETP. 19 Subsequently, reduction of PLOOH by redox-active Met residues of apoAI results in the formation of PLOH and methionine sulfoxides. Preferential degradation of PCOOH by HDL as compared to CEOOH is consistent with the PCOOH location in the surface monolayer of LDL, resulting in their easier accessibility for transfer to HDL. 24 Nonetheless, accumulation of CEOOH in LDL can be inhibited by HDL on LDLϩHDL cooxidation as a consequence of decreased accumulation of PLOOH and shorter chain length of lipid peroxidation. The minor role of HDL-associated enzymes in this mechanism is consistent with their inability to supply reductive equivalents for LOOH reduction.
Dense HDL3 was distinct in accumulating lower levels of PCOOH and CEOOH and inactivating lipid hydroperoxides more potently than HDL2. According to our proposed mechanism, the elevated capacity of HDL3 to incorporate or to inactivate (P)LOOH may derive from (1) depletion of sphingomyelin, (2) enrichment in apoAI, or (3) altered conformation of apoAI as compared to HDL2. 4, 6 The pathophysiological relevance of (P)LOOH inactivation by HDL is highlighted by prooxidative and proinflammatory properties of LOOH. 1 In the arterial intima, free radical-induced peroxidation of LDL lipids results in the formation of LOOH as primary products. 1 We used AAPH, a well-characterized azo-initiator of oxidation, to model free radical-induced LDL oxidation which involves LOOH formation as a major step. 21 Furthermore, the HDL to LDL ratio used in our experiments was close to that in the interstitial fluid. 30 Together with glutathione peroxidase (GPx), apoA-I represents a key LOOH-reducing protein in human plasma. 31 LOOH reduction mediated by apoAI might therefore be especially relevant in microenvironments depleted of lowmolecular-weight compounds, including glutathione and GPx, such as the arterial intima.
The capacity of HDL3 to protect LDL from free radicalinduced oxidative damage is deficient in the atherogenic dyslipidemias of type 2 diabetes and metabolic syndrome. 14 Elevation in the rigidity of the PL monolayer or deficiency of apoAI may underlie this observation. We therefore propose that induction of selective increase in the concentration of functional HDL3 particles displaying decreased surface rigidity and rich in apoAI may constitute an efficacious therapeutic approach to attenuate oxidative damage, inflammation, and atherosclerosis in dyslipidemic subjects at high cardiovascular risk. . Two-step mechanism for HDL3-mediated protection of LDL against oxidative damage induced by free radicals. Initially, PLOOH is transferred from LDL to HDL in a process modulated by the rigidity of the HDL PL monolayer; PLOOH reduction by redox-active Met of apoAI with the formation of PLOH and methionine sulfoxide MetS(O) ensues. PLOOH are preferentially degraded by HDL as compared to CEOOH as PLOOH are located in the surface monolayer of LDL and are more readily accessible for transfer to HDL. 24 
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